Invesco Nasdaq Biotech UCITS ETF Acc
0.40%
465M
465M USDHigh
271
Physical
Accumulating
USD
IE
Nasdaq Biotechnology
Invesco
2014-12-05 (11 years)
With 465M in assets, this is a mid-sized fund — decent liquidity for most investors.
A TER of 0.40% is in line with the market average (~0.35%).
Launched in 2014-12-05, this fund has 11 years of history — long and reliable track record.
High risk — suited for long-term investors comfortable with volatility.
Simulated from available data points. Past returns do not guarantee future results.
| Period | Ann. Return | Cumulative |
|---|---|---|
| 1 Month (est.) | — | +3.2% |
| 3 Months (est.) | — | +9.9% |
| 6 Months (est.) | — | +20.8% |
| YTD (est.) | — | +17.0% |
| 1 Year | +45.9% | +45.9% |
| 3 Years | +17.1% | +60.4% |
| 5 Years | +4.5% | +24.7% |
| Since inception (11y) | +22.5% | +830.5% |
271
59.9%
18.9%
18.0%
18.8%
1.93
0.78
0.18
0.40%
-32.3%
0.18
18.8%
Select your country in the menu to see available brokers and wrappers.
The Invesco Nasdaq Biotech UCITS ETF Acc tracks the Nasdaq Biotechnology index. It is managed by Invesco using physical replication and follows a accumulating distribution policy. The fund is denominated in USD and domiciled in IE. It has a total expense ratio (TER) of 0.40%.
This ranking is for informational purposes only and does not constitute a recommendation to buy or sell any security. Displayed performance is simulated.